PARP inhibitors are poly ADP ribose polymerase and are developed for multiple indications including treatment of heritable cancers. Several forms are dependent on PARP rather than regular cells, making PARP an attractive target for cancer therapy. They are considered as potential treatment for acute life threatening disease such as stroke and myocardial infarction.PARP Inhibitor Market was valued at US$ 12.5 billion in 2024 and is projected to grow at a CAGR of 18.3% to reach US$ 67.0 billion by 2034.

The report "PARP Inhibitor Market, By Drug (Lynparza, Niraparib, Rucaparib and Others), By Indication (Ovarian cancer, Breast cancer, Prostate cancer, Lung cancer and Others), By Distribution Channel (Hospital pharmacies, Online pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2034”

Key Highlights:

• In April 2020, GSK expanded its market for cancer therapy Zejula by acquiring Tesaro in US $5 billion and winning FDA approval for the drug in patients for ovarian cancer.
• In July 2019, UT Southwestern Medical Center’s new research covering a mechanism by which drugs attack cancer and suggested that they can be put in many more patients.

Analyst View:

Increasing incidence of cancers is the major growth driver of global PARP inhibitor market. For ovarian cancer treatments there is high demand of PARP inhibitors which drives the market. Various organizations such as WHO, FEAT, and others along with the government are spreading awareness about this condition which is anticipated to facilitate market growth in the forecast period.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “PARP Inhibitor Market, By Drug (Lynparza, Niraparib, Rucaparib and Others), By Indication (Ovarian cancer, Breast cancer, Prostate cancer, Lung cancer and Others), By Distribution Channel (Hospital pharmacies, Online pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2034”

Key Market Insights from the report:

PARP Inhibitor Market was valued at US$ 12.5 billion in 2024 and is projected to grow at a CAGR of 18.3% to reach US$ 67.0 billion by 2034.The Global PARP Inhibitor Market is segmented based on the drug, indication, distribution channel and region.

• On the basis of drug, the global PARP inhibitor market is segmented into Lynparza, niraparib, rucaparib and others.
•  Based on indication, the target market is segmented into ovarian cancer, breast cancer, prostate cancer, lung cancer and others.
• On the basis of distribution channel, the target market is segmented into hospital pharmacies, online pharmacies and others.
• By region, the Global PARP Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the PARP inhibitor market in terms of revenue, due to the developed healthcare system and health awareness among people.

Competitive Landscape:

The key players operating in the PARP inhibitor market includes AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Jiangsu Hengrui Medicine Co., Ltd, Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com